STOCK TITAN
  1. Home
  2. Sec-filings
  3. REGN
  4. [Form 4] REGENERON PHARMACEUTICALS, INC. Insider Trading Activity

Regeneron EVP McCourt sells 2,346 shares

Regeneron’s EVP Commercial reported selling 2,346 REGN shares in early September 2026 under a Rule 10b5-1 trading plan.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. (REGN) executive vice president of Commercial, Marion McCourt, reported open-market sales of company common stock under a Rule 10b5-1 trading plan. On September 3, 2026, she sold 1,131 shares at $857.39 per share, and on September 2, 2026, she sold 1,215 shares at $850.00 per share. A separate entry reports 219 shares of common stock held indirectly through a 401(k) plan as of September 2, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider McCourt Marion
Role EVP Commercial
Sold 2,346 shs ($2.00M)
Type Security Shares Price Value
Sale Common Stock F1 1,131 $857.39 $970K
Sale Common Stock F1 1,215 $850.00 $1.03M
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 12,003 shares (Direct); Common Stock — 219 shares (Indirect, By 401(k) Plan)
Footnotes (1)
  1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
Shares sold September 3, 2026 1,131 shares Regeneron common stock sold by Marion McCourt on September 3, 2026
Price per share September 3, 2026 sale $857.39 per share Sale of 1,131 shares of Regeneron common stock
Shares sold September 2, 2026 1,215 shares Regeneron common stock sold by Marion McCourt on September 2, 2026
Price per share September 2, 2026 sale $850.00 per share Sale of 1,215 shares of Regeneron common stock
Total shares sold in reported transactions 2,346 shares Combined sales on September 2 and 3, 2026 by Marion McCourt
Indirect holdings via 401(k) plan 219 shares Regeneron common stock held indirectly as of September 2, 2026
Rule 10b5-1 plan adoption date February 17, 2026 Plan intended to comply with Rule 10b5-1(c) for the reported dispositions
Rule 10b5-1(c) regulatory
"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
401(k) Plan financial
"Common stock reported as held indirectly by 401(k) Plan"
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
open market or private transaction financial
"Sale in open market or private transaction of Regeneron common stock"

FAQ

What insider transactions did REGN’s executive report in this Form 4?
The executive vice president of Commercial, Marion McCourt, reported two sales totaling 2,346 shares of Regeneron common stock on September 2 and 3, 2026, plus an updated indirect holding of 219 shares in a 401(k) plan as of September 2, 2026.

At what prices were the REGN shares sold by Marion McCourt?
On September 3, 2026, Marion McCourt sold 1,131 REGN shares at $857.39 per share. On September 2, 2026, she sold 1,215 shares at $850.00 per share, both reported as open-market or private transactions in Regeneron common stock.

How many REGN shares did Marion McCourt sell in total in this filing?
The filing reports that Marion McCourt sold a total of 2,346 shares of Regeneron common stock, consisting of 1,215 shares sold on September 2, 2026, and 1,131 shares sold on September 3, 2026, in open-market or private transactions.

Were the REGN insider sales made under a Rule 10b5-1 trading plan?
Yes. A footnote states that the dispositions were made pursuant to a plan intended to comply with Rule 10b5-1(c) that was adopted on February 17, 2026, and the filing indicates the Rule 10b5-1 plan status as affirmed.

What indirect REGN holdings does Marion McCourt report?
As of September 2, 2026, Marion McCourt reports 219 shares of Regeneron common stock held indirectly through a 401(k) plan. This is shown separately from her directly held shares involved in the reported sales.

Does the Form 4 state Marion McCourt’s total REGN holdings after these sales?
The Form 4 provides an updated figure of 219 indirectly held shares in a 401(k) plan as of September 2, 2026, but it does not state a total number of directly held shares following the reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McCourt Marion
(Last)(First)(Middle)
777 OLD SAW MILL RIVER ROAD
(Street)
TARRYTOWN NEW YORK 10591
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP Commercial
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/02/2026S(1)1,215D$85013,134D
Common Stock09/03/2026S(1)1,131D$857.3912,003D
Common Stock219IBy 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
/s/ Marion McCourt09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR